Loading…
Esperion Therapeutics, Inc. is projected to rise to $3.31 by 2027, a +6% move from its current price of $3.13. ESPR is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $3.04 | $3.13 | $3.22 | -0.04% |
| May 30 | $3.01 | $3.13 | $3.25 | -0.07% |
| May 31 | $2.98 | $3.13 | $3.28 | -0.11% |
| Jun 1 | $2.96 | $3.13 | $3.30 | -0.15% |
| Jun 2 | $2.94 | $3.12 | $3.32 | -0.19% |
| Jun 3 | $2.92 | $3.12 | $3.34 | -0.22% |
| Jun 4 | $2.90 | $3.12 | $3.36 | -0.26% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.90 | $3.12 | $3.36 | -0.26% |
| Week 2 | $2.81 | $3.11 | $3.45 | -0.52% |
| Week 3 | $2.74 | $3.11 | $3.53 | -0.78% |
| Week 4 | $2.68 | $3.10 | $3.59 | -1.03% |
| Week 5 | $2.62 | $3.09 | $3.64 | -1.29% |
| Week 6 | $2.58 | $3.08 | $3.69 | -1.55% |
| Week 7 | $2.53 | $3.07 | $3.73 | -1.80% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Esperion Therapeutics, Inc. is a biopharmaceutical company that develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States.
Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C.
Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH.
Esperion Therapeutics, Inc. was formerly known as HDL Therapeutics, Inc. and changed its name to Esperion Therapeutics, Inc. in May 2008. The company was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Esperion Therapeutics, Inc. (ESPR) is a healthcare stock focused on LDL-C lowering therapies. The current price is $3.13, with a market cap of $805.76M and a rank of 2690.
The price outlook is bullish over the long term, with averages projected to rise from $3.13 in 2026 to $18.26 in 2050, and maximums reaching $34.76 by 2050. The forecast also shows a progression of yearly averages from 2026 through 2050, with notable milestones such as 2029 avg $4.24, 2030 avg $4.79, and 2035 avg $6.18, supporting a bullish longer-term trajectory.
A major floor 52.4% below — a decisive break under it would weaken the trend.
The nearest floor, 39.0% below — buyers have tended to step in here.
Price is pressing into resistance (0.6% away) — a breakout level to watch.
A major ceiling 26.8% above — clearing it would confirm fresh momentum.
Key ESPR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ESPR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.13 | Buy | $3.13 | Buy |
| MA 10 | $3.13 | Buy | $3.10 | Buy |
| MA 20 | $3.01 | Buy | $2.96 | Buy |
| MA 50 | $2.61 | Buy | $2.81 | Buy |
| MA 100 | $2.94 | Buy | $2.84 | Buy |
| MA 200 | $2.93 | Buy | $2.73 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 71.35 | Sell |
| Stoch RSI (14) | 23.89 | Neutral |
| CCI (20) | 37.74 | Neutral |
| Williams %R (14) | -50.00 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -0.32 | Sell |
| Bollinger %B (20,2) | 0.58 | Neutral |
| Stochastic %K (14) | 50.00 | Neutral |
| TRIX (15) | 1.11 | Buy |
| Awesome (5,34) | 0.52 | Buy |
| Ultimate (7,14,28) | 59.77 | Neutral |
| Momentum (10) | 0.00 | Neutral |
| Aroon Osc (25) | 20.00 | Buy |
| Hull MA (9) | 3.13 | Buy |
| ADX (14) | 40.47 | Buy |
| ATR (14) | 0.04 | Info |
The 30-day technical picture is mixed but leaning neutral, with RSI14 at 70, indicating near-overbought conditions on a short horizon. The stock is trading above the SMA50 ($2.59) and SMA200 ($2.92), which can be supportive indicators for price action in the near term.
Key near-term levels include a support at $1.91 and a resistance at $3.15. The 30-day trading range spans $2.58 to $3.80, offering a compact range for momentum assessment in the coming weeks. The stock’s annualized volatility sits at 60%, underscoring substantial price movement potential relative to the broader market.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.91 | $3.13 | $4.07 | 0% | Neutral | |
| $2.62 | $3.31 | $4.43 | +6% | Neutral | |
| $2.88 | $3.73 | $5.18 | +19% | Neutral | |
| $3.28 | $4.35 | $6.21 | +39% | Bullish | |
| $3.65 | $4.95 | $7.24 | +58% | Bullish | |
| $3.88 | $5.36 | $8.01 | +71% | Bullish | |
| $3.85 | $5.42 | $8.24 | +73% | Bullish | |
| $3.87 | $5.53 | $8.57 | +77% | Bullish | |
| $3.88 | $5.63 | $8.86 | +80% | Bullish | |
| $4.42 | $6.51 | $10.40 | +108% | Bullish | |
| $5.43 | $8.56 | $14.54 | +173% | Bullish | |
| $10.96 | $19.42 | $36.11 | +521% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.91 | $3.13 | $3.68 | +0.00% |
| June 2026 | $2.64 | $3.10 | $3.73 | -0.87% |
| July 2026 | $2.55 | $3.03 | $3.69 | -2.48% |
| August 2026 | $2.58 | $3.08 | $3.80 | +1.79% |
| September 2026 | $2.60 | $3.11 | $3.87 | +1.13% |
| October 2026 | $2.52 | $3.04 | $3.81 | -2.45% |
| November 2026 | $2.53 | $3.06 | $3.86 | +0.65% |
| December 2026 | $2.64 | $3.21 | $4.07 | +4.91% |
Click any year to see its month-by-month ESPR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ESPR price prediction for 2026 points to an average of $3.13 (low $1.91, high $4.07) — a potential gain of 0% on today's $3.13. A consolidation phase looks the most probable path here.
In 2027, ESPR is projected to trade between $2.62 and $4.43, averaging $3.31 — a potential gain of +6% from today's $3.13. That is up +6% on the projected 2026 average. Price action looks broadly range-bound.
Esperion Therapeutics, Inc.'s 2028 outlook centres on $3.73, within a $2.88 to $5.18 range. That is up +13% on the projected 2027 average. That marks a +19% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, ESPR could reach as high as $6.21, with a base case around $4.35 and support toward $3.28 — roughly +39% from $3.13. Momentum favours further upside here.
Expect ESPR to range from $3.65 to $7.24 through 2030. The $4.95 average target implies a +58% move from current prices. That is up +14% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The ESPR price prediction for 2031 points to an average of $5.36 (low $3.88, high $8.01) — a potential gain of +71% on today's $3.13. Momentum favours further upside here.
In 2032, ESPR is projected to trade between $3.85 and $8.24, averaging $5.42 — a potential gain of +73% from today's $3.13. That is up +1% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Esperion Therapeutics, Inc.'s 2033 outlook centres on $5.53, within a $3.87 to $8.57 range. That is up +2% on the projected 2032 average. That marks a +77% change versus current levels. Momentum favours further upside here.
By 2034, ESPR could reach as high as $8.86, with a base case around $5.63 and support toward $3.88 — roughly +80% from $3.13. Buyers look set to stay in control over this stretch.
Expect ESPR to range from $4.42 to $10.40 through 2035. The $6.51 average target implies a +108% move from current prices. That is up +16% on the projected 2034 average. Momentum favours further upside here.
The ESPR price prediction for 2040 points to an average of $8.56 (low $5.43, high $14.54) — a potential gain of +173% on today's $3.13. Buyers look set to stay in control over this stretch.
In 2050, ESPR is projected to trade between $10.96 and $36.11, averaging $19.42 — a potential gain of +521% from today's $3.13. That is up +127% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in ESPR today (≈ 319.488818 ESPR) could be worth
$6,205.61
+$5,205.61 (+521%) by 2050 · US Dollar
Based on the average projected ESPR price of $19.42 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ESPRwould be worth at today's price.
$1,000 invested in ESPR on May 27, 2025 (≈ 1,219.512206 ESPR) would be worth
$3,817.07
+$2,817.07 (+281.7%) today · 3.82× · US Dollar
Based on a ESPR entry price of $0.82 vs. today's $3.13.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.13 | $1,000 | -0.0% |
| 1 month ago | $1.91 | $1,638.74 | +63.9% |
| 3 months ago | $3.36 | $931.55 | -6.8% |
| 6 months ago | $4.01 | $780.55 | -21.9% |
| 1 year ago | $0.82 | $3,817.07 | +281.7% |
| All time (5.0y) ago | $20.13 | $155.49 | -84.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ESPR forecast.
Our base-case forecast reaches $6.30 around 2035.
Implied market cap at $6.30: $1.62B
The multi-year forecast shows a steady rise in average price and expanding upside. In 2026 the average forecast price is $3.13, rising through 2027 to $3.23 and 2028 to $3.64, with 2029 averaging $4.24 and 2030 at $4.79. By 2031 the average is $5.23, 2032 $5.22, 2033 $5.25, 2034 $5.37 and 2035 $6.18, all with bullish or neutral sentiment in the near term.
Looking further out, the 2040 forecast shows an average price of $8.03 with a max of $13.92 and a bullish sentiment, while 2050 projects an average of $18.26, a max of $34.76, and a bull outlook with a ROI of 483.3%. The longer horizon implies meaningful upside potential but remains subject to the usual market and regulatory uncertainties; these are estimates, not guarantees.
Tap a question to reveal the answer.
In 2030 the forecast shows min $3.50, avg $4.79, max $7.10 with a ROI of 53.2% and a bullish sentiment.
Yes. The forecast turns bullish from 2029 onward, with 2029 avg $4.24, 2030 avg $4.79, 2040 avg $8.03, and 2050 avg $18.26; ROI increases to 483.3% by 2050.
Yes. The forecast shows a 2035 max of $10.04, with higher upside later (2040 max $13.92 and 2050 max $34.76).
Current price is $3.13 and market cap is $805.76M.
The 30-day range is $2.58 to $3.80.
Esperion Therapeutics, Inc. Community Discussion
0Share your Esperion Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.